Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
- Status
- UNKNOWN
- Phase
- PHASE2
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
- Status
- COMPLETED
- Phase
- PHASE2
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE1
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE1
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib in Operable Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE2
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2